DDInter1561 DDInter1657
Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first approved by the FDA in May 2013 and is currently marketed under the brand name Xofigo, which was formerly called Alpharadin. Xofigo is indicated in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant. The FDA label includes a warning that Radium Ra 223 Dichloride should not be used in women who are pregnant or may become pregnant due to the high risk of fetal harm.
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with [bortezomib] and [dexamethasone], is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells.[L7117,L7120,L10145] This condition is typically treated with high dose [bortezomib] and [dexamethasone] chemotherapy followed by an autologous stem-cell transplant. Other chemotherapies for multiple myeloma include [lenalidomide] and [dexamethasone], [thalidomide], and may include [melphalan] if the patient is not eligible for transplant. Selinexor was also granted accelerated approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that have gone through at least 2 lines of systemic therapy. The FDA approved Selinexor in June 2019. The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.
Radium Ra 223 dichloride {u} (Compound) causes {v} (Side Effect) Extravasation
Radium Ra 223 dichloride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lomustine
Radium Ra 223 dichloride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sarilumab
Radium Ra 223 dichloride {u} may lead to a major life threatening interaction when taken with {v} Abiraterone
Radium Ra 223 dichloride (Compound) causes Extravasation (Side Effect)
Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken with Lomustine
Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Radium Ra 223 dichloride may lead to a major life threatening interaction when taken with Abiraterone